You are here

INTERCEPT

89Bio Enlivened by Nash success

89Bio Enlivened by Nash success

EP Vantage

Akero Therapeutics

Madrigal Pharmaceuticals

Flag link:

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

CP Wire

primary biliary cholangitis

obeticholic acid

Flag link:

Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients

primary biliary cholangitis

obeticholic acid

Flag link:

OraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays

OraSure Technologies and Roche Announce FDA 510(k) Clearance for Four Fully Automated Oral Fluid Drugs of Abuse Assays

Flag link:

Adoption of Cerus' Technology Makes Its Valuation Look Ridiculous

Adoption of Cerus' Technology Makes Its Valuation Look Ridiculous

Seeking Alpha

Flag link:

Short Blood Supply Means Long Outlook for Cerus

Short Blood Supply Means Long Outlook for Cerus

Seeking Alpha

Flag link: